China Biologic Products (01177.HK) plans to spend no more than 2 billion Hong Kong dollars on share repurchases and rewarding share purchases.

Zhixin Finance APP News, China Biopharmaceuticals (01177.HK) announced that on June 12, 2026, the board of directors passed a share purchase plan. According to this plan, the company will, depending on market conditions, purchase shares in the open market for a total price not exceeding 2 billion Hong Kong dollars within the next 12 months. This includes (1) repurchasing shares based on the share repurchase authorization granted at the annual general meeting of shareholders, subject to its terms and conditions, and (2) instructing the trustee responsible for managing the share incentive plan adopted by the company on January 5, 2018 to purchase shares. The board of directors will periodically review and fully decide how to allocate the share purchase amount for share buybacks and incentived share purchases.